Topics:

Rheumatology Network

Will You Buy In on the Next Biosimilar?

The FDA has deferred a scheduled meeting about Remsima, the infliximab biosimilar already approved in Europe and still awaiting judgment in the US. But approval of the first US biosimilar (a version of the cancer drug filgrastim) prompted warnings from two organizations concerned with rheumatic disease, including the ACR. Are you ready the next challenge to your clinical judgment?

Recent Content

scleroderma

A general overview of the fibrosis process discusses mechanisms and cell pathways in brief while focusing on clinical issues.

Over five years, in the randomized GO-REVEAL study, golimumab helped more than half of psoriatic arthritis patients achieve minimal disease activity.

Although studies of ultrasound diagnosis for gout are scarce, the authors of two reviews maintain the evidence is good that it is a useful option--and may be leading to some revisions in the way the condition is detectedl.

About 30% of rheumatologists don't pre-test patients for hepatitis B before prescribing immunosuppressant medications. These authors offer new guidance for screening.

(AAOS2015) Evidence from large insurance databases shows that knee replacement often quickly follows arthroscopy or injections. It would make (economic and clinical) sense to go straight to surgery, the researchers contend.

Tech Tips: In Part I, Dr. Bhana gave advice about sorting through the barrage of clinical journal articles that rheumatologists face every month. Here, in Part II, he shows how to save and file your choices for easy access in the future.

Women who use acetaminophen or NSAIDs regularly for years appear to be at increased risk for psoriatic arthritis, data from the Nurses Health Study reveal.

By clicking Accept, you agree to become a member of the UBM Medica Community.